NCT07307989

Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis

Early Statin-Ezetimibe Combination vs. Statin Monotherapy to Achieve LDL-C < 70 mg/dL in Recent Ischemic Stroke Patients With Evidence of Atherosclerosis: A Randomized Controlled Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Chang Gung Memorial Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

This study will be conducted at six medical institutions in Taiwan, recruiting patients who visit neurology outpatient clinics or are hospitalized within 30 days after an ischemic stroke. Participants will be randomly assigned to either the experimental group (moderate-intensity statin plus ezetimibe) or the control group (moderate- or high-intensity statin). Research assistants will screen patients aged 40 or older who have had an ischemic stroke or transient ischemic attack within 30 days, have atherosclerosis, and have LDL-C levels ≥100 mg/dL. Eligible cases will be reviewed by the attending physician. With physician approval, patients will be invited to join the study, and those who agree and sign informed consent will be enrolled.

Conditions

• Ischemic Stroke
• Hypercholesteremia

Interventions

Type	Name	Description
DRUG	statin + ezetimibe	Moderate-intensity statin plus ezetimibe 10mg
DRUG	Statin monotherapy (rosuvastatin or atorvastatin)	Moderate- or high-intensity statin monotherapy

Timeline

• Start date: 2025-08-01
• Primary completion: 2029-07-31
• Completion: 2029-07-31
• First posted: 2025-12-29
• Last updated: 2025-12-30

Locations

1 site across 1 country: Taiwan